IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1 – 218 (Cancelled).

Claim 219. (New) A solid oral dosage form, comprising:

(a) at least one proton pump inhibitor selected from the group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole and pantoprazole, or an enantiomer, isomer, prodrug, free base, or salt thereof wherein at least some of the proton pump inhibitor is not enteric coated;

(b) a buffering agent comprising sodium bicarbonate; and

(c) one or more optional excipients;

wherein upon oral administration of the solid oral dosage form to a subject, the subject exhibits a T_{max} of said proton pump inhibitor within about 1 hour after administration.

Claim 220. (New) The solid oral dosage form of claim 219, wherein the buffering agent is present in an amount sufficient to preserve the ability of at least some of the proton pump inhibitor to elicit a therapeutic effect.

Claim 221. (New) The solid oral dosage form of claim 219, wherein the buffering agent is present in an amount sufficient to increase the pH of the stomach contents of a subject to a pH that prevents or inhibits acid degradation of at least some of the proton pump inhibitor.

Claim 222. (New) The solid oral dosage form of claim 219, wherein the buffering agent is present in a total amount of about 3 mEq to about 45 mEq.

Claim 223. (New) The solid oral dosage form of claim 219, wherein the buffering agent is present in a total amount of at least about 3 mEq.

Claim 224. (New) The solid oral dosage form of claim 219, wherein the sodium bicarbonate is present in an amount of about 250 mg to about 4000 mg.

Claim 225. (New) The solid oral dosage form of claim 219, wherein the sodium bicarbonate is present in an amount of about 4 mEq to about 30 mEq.

Claim 226. (New) The solid oral dosage form of claim 219, wherein the buffering agent further comprises a buffering agent selected from the group consisting of potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium aluminate, magnesium carbonate, magnesium silicate, aluminum hydroxide, potassium carbonate, potassium citrate, aluminum hydroxide/sodium bicarbonate coprecipitate, aluminum magnesium hydroxide, sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, calcium acetate, calcium glycerophosphate, calcium hydroxide, calcium lactate, calcium carbonate, and calcium gluconate, calcium bicarbonate, calcium citrate, sodium phosphate, or mixtures thereof.

Claim 227. (New) The solid oral dosage form of claim 219, wherein the buffering agent further comprises a buffering agent selected from the group consisting of magnesium hydroxide, magnesium oxide, potassium carbonate, sodium carbonate, calcium carbonate, calcium bicarbonate, or mixtures thereof.

Claim 228. (New) The solid oral dosage form of claim 219, wherein the buffering agent further comprises a buffering agent selected from the group consisting of sodium carbonate or calcium carbonate.

Claim 229. (New) The solid oral dosage form of claim 219, wherein the buffering agent further comprises magnesium hydroxide.

Claim 230. (New) The solid oral dosage form of claim 219, wherein the solid oral dosage form is selected from the group consisting of a tablet, a capsule, a pellet, a granule, or a troche.

Claim 231. (New) The solid oral dosage form of claim 219, wherein the solid oral dosage form is a tablet.

Claim 232. (New) The solid oral dosage form of claim 231, wherein the tablet is a chewable tablet.

Claim 233. (New) The solid oral dosage form of claim 219, wherein the solid oral dosage form is a capsule.

Claim 234. (New) The solid oral dosage form of claim 219, wherein the proton pump inhibitor is present in an amount of about 10 mg to about 100 mg.

Claim 235. (New) The solid oral dosage form of claim 219, wherein the proton pump inhibitor is present in an amount of about 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, or 60 mg.

Claim 236. (New) The solid oral dosage form of claim 219, wherein the proton pump inhibitor is omeprazole or an enantiomer, isomer, free base, salt, or mixture thereof.

Claim 237. (New) The solid oral dosage form of claim 219, wherein the proton pump inhibitor is lansoprazole or an enantiomer, isomer, free base, salt, or mixture thereof.

Claim 238. (New) The solid oral dosage form of claim 219, wherein the proton pump inhibitor is esomeprazole or an enantiomer, isomer, free base salt, or mixture thereof.

Claim 239. (New) The solid oral dosage form of claim 219, wherein the excipient comprises a binder.

Claim 240. (New) The solid oral dosage form of claim 239, wherein the binder is hydroxypropylmethylcellulose.

Claim 241. (New) The solid oral dosage form of claim 219, wherein the excipient comprises a flavoring agent.

Claim 242. (New) The solid oral dosage form of claim 219, wherein the excipient comprises a disintegrant.

Claim 243. (New) The solid oral dosage form of claim 242, wherein the dosage form is a capsule.

Claim 244. (New) The solid oral dosage form of claim 242, wherein the excipient comprises a lubricant.

Claim 245. (New) The solid oral dosage form of claim 242, wherein the proton pump inhibitor is micronized.

Claim 246. (New) The solid oral dosage form of claim 219, wherein at least some of the proton pump inhibitor is enteric coated.

Claim 247. (New) The solid oral dosage form of claim 219, wherein within 5 minutes after administration of the solid oral dosage form to the subject, the pH of the subject's stomach is equal to or greater than the essential pH of the proton pump inhibitor.

Claim 248. (New) The solid oral dosage form of claim 219, wherein upon administration of the solid oral dosage form to the subject, the subject exhibits a Tmax within about 45 minutes after administration.

Claim 249. (New) The solid oral dosage form of claim 219, wherein upon administration of the solid oral dosage form to the subject, the subject exhibits an average plasma concentration of at least about 1.0 μg/ml at any time within about 40 minutes after administration.

Claim 250. (New) The solid oral dosage form of claim 219, wherein upon administration of the solid oral dosage form to the subject, the subject exhibits an average plasma concentration of at least about 0.1 μg/ml at any time within about 15 minutes after administration.

Claim 251. (New) A method of administering a proton pump inhibitor to a subject, comprising the steps of:

(a) providing a solid oral dosage form, comprising:

(i) at least one proton pump inhibitor selected from the group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole and pantoprazole, or an enantiomer, isomer, free base, salt, or mixture thereof wherein at least some of the proton pump inhibitor is not enteric coated;

(ii) at least one buffering agent wherein the buffering agent is present in an amount sufficient to increase the pH of the stomach contents of a subject to a pH that prevents or inhibits acid degradation of at least some of the proton pump inhibitor; and

(iii) one or more optional excipients; and

(b) orally administering the solid oral dosage form to the subject;

wherein upon oral administration of the solid oral dosage form to a subject, the subject exhibits a T_{max} of the proton pump inhibitor within about 1 hour after administration; and

wherein the method does not include administration of a poly[phosphoryl/sulfon]-ated carbohydrate to the subject.

Claim 252. (New) The method of claim 251, wherein the proton pump inhibitor is present in an amount of about 10 mg to about 100 mg.

Claim 253. (New) The method of claim 251, wherein the proton pump inhibitor is present in an amount of about 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, or 60 mg.

Claim 254. (New) The method of claim 251, wherein the proton pump inhibitor is omeprazole or an enantiomer, isomer, free base, salt, or mixture thereof.

Claim 255. (New) The method of claim 251, wherein the proton pump inhibitor is lansoprazole or an enantiomer, isomer, free base, salt, or mixture thereof.

Claim 256. (New) The method of claim 251, wherein the proton pump inhibitor is esomeprazole or an enantiomer, isomer, free base salt, or mixture thereof.

Claim 257. (New) The method of claim 251, wherein the solid oral dosage form further comprises a binder.

Claim 258. (New) The method of claim 251, wherein the solid oral dosage form further comprises a flavoring agent.

Claim 259. (New) The method of claim 251, wherein the solid oral dosage form further comprises a disintegrant.

Claim 260. (New) The method of claim 251, wherein the buffering agent is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium aluminate, magnesium carbonate, magnesium silicate, aluminum hydroxide, potassium carbonate, potassium citrate, aluminum hydroxide/sodium bicarbonate coprecipitate, aluminum magnesium hydroxide, sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, calcium acetate, calcium glycerophosphate, calcium hydroxide, calcium lactate, calcium carbonate, and calcium gluconate, calcium bicarbonate, calcium citrate, sodium phosphate, or mixtures thereof.

Claim 261. (New) The method of claim 251, wherein the buffering agent is present in a total amount of about 3 mEq to about 45 mEq.

Claim 262. (New) The method of claim 251, wherein the buffering agent is present in a total amount of at least about 3 mEq.

Claim 263. (New) The method of claim 251, wherein the buffering agent comprises sodium bicarbonate in an amount of about 250 mg to about 4000 mgs.

Claim 264. (New) The method of claim 251, wherein the buffering agent is selected from the group consisting of sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium hydroxide, or mixtures thereof.

Claim 265. (New) The method of claim 261, wherein the proton pump inhibitor is micronized.

Claim 266. (New) The method of claim 261, wherein the solid oral dosage form is selected from the group consisting of a tablet, a capsule, a powder, a pellet, a granule, or a troche.

Claim 267. (New) The method of claim 266, wherein the solid oral dosage form is a tablet.

Claim 268. (New) The method of claim 266, wherein the solid oral dosage form is a capsule.

Claim 269. (New) The method of claim 267, wherein the tablet is a chewable tablet.

Claim 270. (New) The method of claim 251, wherein within 5 minutes after administration of the solid oral dosage form to the subject, the pH of the subject's stomach is equal to or greater than the essential pH of the proton pump inhibitor.

Claim 271. (New) The method of claim 251, wherein upon administration of the solid oral dosage form to the subject, the subject exhibits an average plasma concentration of at least about 1.0 μg/ml at any time within about 40 minutes after administration.

Claim 272. (New) The method of claim 251, wherein upon administration of the solid oral dosage form to the subject, the subject exhibits an average plasma concentration of at least about 0.1 μg/ml at any time within about 15 minutes after administration.